India, Aug. 24 -- Scinai Immunotherapeutics (SCNI), a biopharmaceutical company, on Monday released financial results for the first half of 2026, and turned a profit for the period after incurring a loss in the previous year.
The Israeli company has been developing various therapies for immunological skin diseases. Its pipeline includes the PC111 monoclonal antibody (mAb) for toxic epidermolysis necrosis (TEN) and pemphigus, and a bispecific IL-17 nano-antibody (NanoAb) developed for psoriasis and hidradenitis suppurativa (HS).
H1 Financial Results:
The company reported a net income of $1.6 million in the first half of 2026, while in the same period of 2025, Scinai incurred a net loss of $4.1 million. This may be attributed to the $6.4 m...